Tofacinix (Tofacitinib) is a tablet formulation manufactured by Beacon Pharmaceuticals Ltd. It is available in packs of 3×10’s Alu-Alu, with a strength of 11 mg. Tofacinix falls under categories such as Anti-viral, Biotech Products, and Drugs to treat Hepatitis.

Indications:
Tofacitinib is indicated for the treatment of:
– Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate, either as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.
– Active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other DMARDs.
– Moderately to severely active ulcerative colitis in adults.

Pharmacology:
Rheumatoid arthritis involves dysregulation of pro-inflammatory cytokines like IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta, leading to tissue inflammation and joint damage via the Janus kinase signaling pathway. Tofacitinib, a partial and reversible Janus kinase (JAK) inhibitor, prevents the body from responding to cytokine signals by inhibiting JAKs, thus reducing inflammation and joint damage.

Dosage & Administration:
Dosage recommendations vary based on the condition:
– Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Adjustments are needed for patients with renal or hepatic impairment.
– Psoriatic Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily, with dosage adjustments for impaired renal or hepatic function.
– Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks, then adjust to 5 or 10 mg twice daily. Dosage reduction is necessary for patients with renal or hepatic impairment.

Interaction:
Tofacitinib may interact with potent inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4), leading to dose adjustments.

Contraindications:
There are no contraindications for Tofacitinib use.

Side Effects:
Common adverse reactions include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis.

Pregnancy & Lactation:
Tofacitinib is Pregnancy Category C, and its use during pregnancy should be carefully considered. Its excretion in human milk is uncertain, so nursing mothers should weigh the benefits against potential risks.

Precautions:
Special precautions are advised for serious infections, gastrointestinal perforations, laboratory monitoring, and immunizations with live vaccines.

Use in Special Populations:
The safety and effectiveness of Tofacitinib in pediatric patients have not been established, and caution should be exercised when treating elderly patients.

Storage Conditions:
Tofacitinib should be stored at temperatures between 20°C to 25°C.